康緣藥業(600557.SH):澤瀉降脂膠囊獲批臨牀試驗
格隆匯 7 月 30日丨康緣藥業(600557.SH)公佈,近日,公司收到國家藥品監督管理局核准簽發的澤瀉降脂膠囊《藥物臨牀試驗批准通知書》,同意該藥品進行臨牀試驗。
澤瀉始載於《神農本草經》,為《中國藥典》收錄品種,具有利水滲濕,泄熱,化濁降脂的功效;用於小便不利,水腫脹滿,泄瀉尿少,痰飲眩暈,熱淋澀痛,高脂血症。2002年,澤瀉被我國原衞生部列入可用於保健食品的名單。
澤瀉降脂膠囊為我公司與上海現代藥物製劑工程研究中心有限公司合作開發的中藥5類新藥,功能主治泄熱滲濕,化濁降脂,用於痰濁阻遏所致的頭重如裹,胸悶,嘔惡痰涎,肢麻沉重,形體肥胖;高脂血症見上述症候者。江蘇康緣藥業股份有限公司與上海現代藥物製劑工程研究中心有限公司共同擁有該產品的知識產權。
截至目前,公司累計研發投入約3898.20萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.